Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843475 | 0.98 | FFAR1 (0.59) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL9098252 | 0.98 | FFAR1 (0.59) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL947314 | 0.95 | FFAR1 (0.59) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL465524 | 0.91 | HPGD (0.67) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL1299974 | 0.90 | RAB9A (0.61) | FFAR1HPGDALDH1A1LMNAMAPT | |
| SCHEMBL465467 | 0.90 | ALDH1A1 (0.65) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL465533 | 0.90 | ALDH1A1 (0.65) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL2233399 | 0.88 | HPGD (0.58) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| Hydrocinnamyl Alcohol SCHEMBL3852895 | 0.88 | LTA4H (0.59) | FFAR1HPGDS1PR1ALDH1A1LMNA | |
| SCHEMBL3562374 | 0.88 | KCNA3 (0.64) | HPGDALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661892-B1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| CN-1845911-B | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO | 2012-07-04 | — | — | CN | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| EP-1575964-B1 | N-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATES, PHOSPHONATES AND TETRAZOLES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7479504-B2 | Edg receptor agonists | MERCK & CO., INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| EP-0180897-B1 | 5-FLUOROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-07 | — | — | EP | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | FFAR1 1005/4885HPGD 100/4885S1PR1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.